http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-9815784-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05ff905fdc49089f5f25746eaeb40190
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D279-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-538
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D279-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06
filingDate 1998-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a1fa0710657d807b260537a68004e31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1d1a32e0e310e10cdad3dd98df20d95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_125e5b22e53d9ef5e0e81268793a6630
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5162a0a646386d91eab2494ae919d8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64a47f478ae81e4c1075900f1a1aeddf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e59fceb9e9164330f3d4b2fcdaba074
publicationDate 2000-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-9815784-A
titleOfInvention Benzoxazinones / benzothiazinones as serine protease inhibitors
abstract Invention Patent: <B> "BENZOXAZINONES / BENZOTIAZINONES AS SERINE PROTEASE INHIBITORS" <D>. The present invention relates to benzoxazinone and benzothiazinone compounds, which have inhibitory effects on serine proteases such as factor Xa, thrombin and / or factor VIIa. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for the treatment or prevention of disease states in mammals characterized by abnormal thrombosis.
priorityDate 1998-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID431577138
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID90470996
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP84122
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422138360
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54075749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419742006
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19937448

Total number of triples: 35.